Biểu đồ giá cổ phiếu ALNY
ALNY Giá
Alnylam Pharmaceuticals Inc
$296.11
-4.32%
$-13.37
Khi đóng cửa: May 01, 16:00:00 GMT-4
$299
0.97%
$2.88
Phiên trước giờ: May 04, 08:14:27 GMT-4
Quay lại
Alnylam Pharmaceuticals Inc (ALNY) Giá
Thống kê chính
Giá đóng cửa trước
$309.49
Giá mở cửa
$307.46
Phạm vi ngày
$295.79 - $311.88
Phạm vi 52 tuần
$214.76 - $495.55
Khối lượng
1.1M
Khối lượng trung bình
1.4M
Tỷ suất cổ tức
--
EPS (TTM)
2.25
Vốn hóa thị trường
$39.6B
ALNY là gì?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
